---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-002729"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2023-02-14T23:59:59+00:00"
generated_at: "2026-06-19T14:05:11.328001+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# Prelude Therapeutics posts investor presentation for SVB Global Biopharma Conference

## Summary
- Filed investor presentation under Regulation FD for Feb 2023 SVB conference.
- Presentation attached as Exhibit 99.1 with no specific financial or clinical details in filing body.
- No new material events, guidance changes, or operational updates disclosed in the 8-K text.

## SEC filing metadata
- accession: 0000950170-23-002729
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2023-02-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000095017023002729/0000950170-23-002729-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000095017023002729/prld-20230214.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-002729
- JSON: https://secwatch.observer/filing/0000950170-23-002729.json
- Plain text: https://secwatch.observer/filing/0000950170-23-002729.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.